TRANSFORMING CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY WITH TARGETED NEUROPROTECTION
Embedded Files
BRINGING NEUROSALVAGE TO NEUROPATHY
Cool Flame Bio is developing a first‑in‑class mitochondrial targeting peptide platform. This platform prevents and treats chemotherapy‑induced peripheral neuropathy (CIPN), aiming to preserve dose intensity and quality of life for cancer patients.
LARGE, UNDERSERVED MARKET
CIPN affects hundreds of thousands of patients globally each year. Even modest reductions in CIPN would have a meaningful impact on patient outcomes, quality of life, and healthcare utilization.
Multi‑billion‑dollar opportunity across major chemotherapies.
Potential for use in both prevention and treatment settings.
Neuroprotection/neurosalvage platform for many other neuropathies including: diabetic, radiation, and compression neuropathies.
Report abuse